Drug Profile
Research programme: intralymphatic house dust mite immunotherapy - ImVisioN
Alternative Names: IVN-mite; Mite-MATLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ImVisioN Therapeutics
- Class Allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Allergy in Germany (Intralymphatic, Injection)